Borenius advised Nanoform on a directed share issue

We advised Nanoform Finland Plc in connection with a directed share issue of approximately EUR 15 million through an accelerated book building procedure.

Nanoform successfully completed the share issue on 24 April 2024. The proceeds from the share issue will be used to accelerate Nanoform’s growth strategy through continued investments, commercialisation and growth of Nanoform’s nanoparticle-enabled formulation platforms for next generation medicines. The placing to leading Nordic and international institutional investors and other qualified investors was carried out based on offers received in an accelerated book building procedure.

Nanoform is an innovative company that contributes to the development of nanoparticle medicine. Nanoform works to improve the lives of patients globally by overcoming drug development and delivery challenges through Nanoform’s game-changing technologies and novel formulation capabilities.